Aequus Pharmaceuticals Inc.
AQSZF
$0.004
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 240.14% | 124.62% | -30.11% | -70.39% | -82.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 240.14% | 124.62% | -30.11% | -70.39% | -82.03% |
| Cost of Revenue | 249.85% | 122.33% | 24.91% | -23.08% | -32.86% |
| Gross Profit | 233.80% | 126.41% | -49.52% | -80.78% | -88.23% |
| SG&A Expenses | -27.41% | -8.86% | -4.35% | -6.78% | -19.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.41% | -13.06% | -9.31% | -9.38% | -20.43% |
| Operating Income | 42.15% | 25.50% | 4.59% | -14.80% | -9.26% |
| Income Before Tax | 27.28% | 27.34% | 18.81% | 4.16% | 6.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 27.28% | 27.34% | 18.81% | 4.16% | 6.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.28% | 27.34% | 18.81% | 4.16% | 6.66% |
| EBIT | 42.15% | 25.50% | 4.59% | -14.80% | -9.26% |
| EBITDA | 45.22% | 25.54% | 4.54% | -14.91% | -9.34% |
| EPS Basic | 26.71% | 26.67% | 18.13% | 3.61% | 6.94% |
| Normalized Basic EPS | 36.63% | 21.15% | 18.42% | 3.85% | 6.48% |
| EPS Diluted | 26.71% | 26.67% | 18.13% | 3.61% | 6.94% |
| Normalized Diluted EPS | 36.63% | 21.15% | 18.42% | 3.85% | 6.48% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |